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Abstract 
 
Objective: In the past decade localized prostate cancer (LPC) management has been 
shifting from three radical treatment options (radical prostatectomy, external beam 
radiotherapy, or brachytherapy) to also include active surveillance (AS). This study 
examines men with LPC and partners’ experiences of choosing between AS and 
radical treatments, and their experiences of AS when selected. 
Methods: Qualitative descriptive research design. Interviewed participants were men, 
and partners of men, who had either chosen radical treatment immediately following 
diagnosis, or who had been on AS for at least three months. AS was the recommended 
treatment. Transcribed interviews were thematically analysed and inter-rater 
reliability integrated.   
Results: Twenty-one men and 14 partners participated. Treatment decisions reflected 
varied reactions to prostate cancer information, regularly described as contradictory, 
confusing, and stressful. Men and partners commonly misunderstood AS but could 
describe monitoring procedures. Partners often held the perception that they were also 
on AS. Men and partners usually coped with AS but were sometimes encumbered by 
treatment decision-making memories, painful biopsies, ongoing conflicting 
information, and unanswered medical questions. Radical treatment was selected when 
cancer progression was feared or medically indicated. Some preferred doctors to 
select treatments.  
Conclusions: To reduce distress frequently experienced by men diagnosed with LPC 
and their partners during treatment decision-making and ongoing AS monitoring, the 
following are needed: improved community and medical awareness of AS; consistent 
information about when radical treatment is required; and consistent, unbiased 
information on treatment options, prognostic indicators, and side effects. Regularly 
up-dated decisional support information/aids incorporating men’s values are 
imperative.  
 
Keywords: cancer, oncology, prostate cancer, active surveillance, qualitative research 
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Background 
 
Until prostate specific antigen (PSA) testing was introduced in the mid-1980s [1] 
detected prostate cancers (PC) were usually advanced and incurable [2]. PSA testing 
has dramatically increased PC incidence, however, many detected cancers are 
localized and well-to-moderately differentiated [3]. Those with well-differentiated 
disease often survive 10–20 years without intervention [3]. Until recently, curative 
treatment was offered to most men with localized prostate cancer (LPC) [4]. Options 
include radical prostatectomy (RP), brachytherapy (BT), and external beam radiation 
therapy (EBRT). Urinary or bowel incontinence and sexual dysfunction, however, are 
common side effects [5]. In 2001-2, active surveillance (AS) emerged as an 
alternative [4].  
AS is a proactive management plan which aims to delay or prevent radical 
treatment (RP, BT, EBRT) by closely monitoring low-risk PC until PSA tests and/or 
repeat biopsies indicate disease progression [6, 7]. AS differs from “watchful waiting” 
which is usually reserved for older men with limited life expectancy and involves 
conservative PC management until disease progression warrants non-curative 
hormone therapy [8]. In 2009, the Urological Society of Australia and New Zealand 
formally acknowledged AS as a treatment option for suitable men [9]. In 2012 the 
National Comprehensive Cancer Network (NCCN) recommended that men with very 
low-risk1 PC (expected survival <20 years) be managed with AS, and men with low2 
or intermediate3 risk PC (expected survival <10 years) be managed by AS or radical 
treatment [10]. In 2014 the NCCN guidelines were amended, removing the option of 
AS for those with intermediate risk PC [11]. Up to 12-year survival rates are similar 
for men with LPC randomized to either observation or RP [12] and RP and 
radiotherapy survival outcomes are also similar [13]. Despite this, estimated AS 
uptake rates for men with LPC are 10% [14] and 42% [15] in American and 
Australian men respectively. Some men with LPC are still not offered AS [16]. 
Amongst those offered AS, some believe that LPC should be immediately removed 
when cancer is curable [17] and families and friends may have similar concerns [6].  
 Previous studies have examined the reasons underpinning men’s choice 
between LPC treatments including AS. Decisions reflect beliefs about cancer, 
knowledge of others’ cancer experiences, partners’ distress, and peer pressure [6, 18]. 
Those choosing AS usually believe their cancer is not aggressive [18], received a 
trusted urologist’s recommendation [18, 19], considered their age and potential 
treatment side-effects [19, 20], and expected to maintain life quality [20]. AS is 
typically rejected because of fear of cancer progression, frequent check-ups [20], the 
need to “do something” [18], and contradictory physician treatment opinions [6].  
 Should AS be selected, reports on men coping are mixed. For example, men 
and partners have reported low anxiety [21] and only 2-18% of men have sought 
treatment without disease progression [7]. Nonetheless, some Canadian men on AS 
found biopsies distressing, feared illness progression, and were uncomfortable talking 
about PC [22]. Partners’ role in men’s treatment decision-making is inconsistently 
reported [22] but they usually wanted men to make the final decision [23]. Only one 
study investigating uncertainty associated with AS was identified which included only 
four partners [24].  
                                                          
1 T1c tumor; PSA level <10 ng/mL and density <0.15 ng/mL/g; Gleason score ≤6; cancer in <3 biopsy 
cores and in ≤50% of any core.  
2 T1a, T1b, T1c, or T2a tumor; PSA <10ng/mL; Gleason score ≤6.   
3 T2b-T2c tumor, or PSA 10-20 ng/mL, or Gleason score 7.  
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 Each treatment option for LPC has specific advantages and disadvantages [6]. 
Increasingly, AS is likely to be the recommended management option, however, there 
have been no studies identified which investigate the psychological aspects of 
treatment decision-making when the AS management option is recommended by the 
treating urologist. In this context, we need to clarify men’s and partners’ needs for 
decisional support so that interventions can be developed to help men select the best 
treatment for their individual situation. Partners’ views are important because they are 
affected by treatment decisions and often significantly impact men’s experience of 
care and decisional satisfaction [25]. This study examined Australian men’s and 
partners’ experience of treatment decision-making following LPC diagnosis and their 
experience of AS when AS was the recommended treatment option. 
 
Methods 
 
Setting and Participants 
 
A qualitative descriptive research design with “grounded theory overtones” [26, 27] 
was used. This means that techniques associated with grounded theory were included, 
i.e., inductive, cyclic, and constant comparative data analysis. Participants were 
recruited from a private urology practice, an integrative cancer centre, and a public 
hospital’s oncology service following ethics approvals. Two urologists involved in the 
study recommended AS as the preferred treatment option to eligible men. Clinical 
eligibility criteria for AS recommendation were: T1-2a tumors, Gleason score ≤6, and 
PSA <10ng/mL. Additionally, one urologist included men with one of: T2b-T2c 
tumor, PSA 10-20 ng/mL, or Gleason score 7. Additional inclusion criteria comprised 
two groups: men newly diagnosed with LPC who declined AS in favour of radical 
treatment; and men who had been on AS for at least three-months following LPC 
diagnosis (they may have since ceased AS). Men could invite partners to participate if 
available. Exclusion criteria comprised men under 18-years and/or experiencing 
cognitive, physical, or psychological difficulties that precluded participation, as 
determined by treating doctor/team.  
 Sampling intent was purposive, which means that recruitment focused on 
potential participants believed to provide a range of understanding of the research 
phenomenon [28]. Qualitative sampling strategies are not intended to achieve 
statistical generalizations. Urologists identified patients according to varied age, 
treatment choice, time on AS, reason for ceasing AS, socio-demographic background, 
and rural/urban dwelling. Between September, 2012, and April, 2013, 85 invitations 
to participate were sent to men across eight mail-out waves with later invitations to 
men with characteristics less evident in earlier collected data. Participant consent 
forms were returned to a research assistant, promoting urologist blinding of 
participation. Interviews were between October, 2012 and end of April, 2013.  
 
Data and Analysis 
 
Consenting participants engaged in individual, semi-structured telephone interviews 
that invited discussion about: helpfulness of information; AS understanding and 
experience; reactions to treatment decision-making; support required/received; and 
suggestions for others dealing with treatment decision-making and AS. Demographic 
information was collected from participants and medical details from men’s medical 
records. 
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 Analysis of transcribed interviews was managed by qualitative data 
management software [29]. Interviews were initially coded, and comparable codes 
grouped into categories which separately represented men’s and partners’ responses. 
Comparable categories from the two data sets were then grouped into themes 
representing both men’s and partners’ responses. Coding labels were created by 
researchers (i.e., not predetermined) to denote text segments, as informed by grounded 
theory. To promote rigour and trustworthiness an inter-rater reliability strategy was 
integrated [30]: All interviews were coded and categorised by either CO or TD (first 
and second authors), both experienced qualitative researchers. They then examined 
each other’s analyses, discussed different code and category interpretations until 
reaching agreement, and together finalised themes. Additionally, AH (third author and 
trained qualitative research interviewer) examined and agreed with the findings.  
 
Results 
 
Twenty-one men and 14 partners participated. Participants’ demographic 
characteristics are in Table 1. Figure 1 illustrates treatment decision-making pathways 
undertaken. Two partner participants were invited by non-participating men who 
either chose immediate treatment on diagnosis or ceased AS on medical advice. 
Twenty-seven percent of invited men and/or their partners participated. Interview 
mean lengths were 38 (men) and 34 (partners) minutes. Men had been or were on AS 
for mean 22 months (range 3-96 months).  
 Findings are organised into the following three themes and seven categories, 
and participants’ recommendations (Table 2). Details in parentheses signify 
participants’ ages, if they were partners (P), and whether men were still on AS (AS), 
had received non-medical reason radical treatment (NT), medical reason radical 
treatment (MT), or after diagnosis chose radical treatment (DT): e.g., (70PMT) 
denotes 70-year-old partner of a man who received medically indicated radical 
treatment following at least three months on AS. 
 
LPC treatment decisions are affected by information gathered and varied 
emotional and relational reactions 
 
Information was satisfactory, contradictory, stressful, and/or misunderstood.  
 
Twelve men were satisfied with PC information received from urologists, even when 
not understanding it. One man stated, “Sometimes (PC) can get better” (59AS). Eight 
were dissatisfied and one could not remember. One man said:  
The original urologist I saw gave me some information … more than five 
years old. … that wasn’t current and I found searching the net, … two 
options, … radical prostatectomy and radiotherapy (and) …, there was 
something else … high intensity focused ultrasound …. Am I reading stuff 
that’s incorrect or is it the difficulty because it’s an evolving thing and 
there’s research … the people I’ve seen aren’t on top of? (60AS) 
 Information from multiple sources, including other doctors, internet, family, 
and friends, could also be limited, and/or confusing. Four men and two partners were 
particularly stressed by conflicting information gathered. “Everybody’s got different 
ideas about it,” one man said (53AS), and his partner indicated,  
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It was very confusing to have doctors who said … “AS is definitely for 
you”, and then to see an oncologist … who said, “Well no, your age group, 
highly unlikely for you”... that took away some of our confidence. (42PAS)  
Disagreement with her husband about seeking second opinions also stressed their 
relationship. Otherwise partners tended to be satisfied with information from medical 
meetings, brochures, friends, and/or the internet, even when receiving information on 
AS and RP exclusively from the urologist. Two partners with unmet information 
needs did not attend husbands’ medical appointments.  
 Some men on AS and partners did not understand nor recall the term AS but 
all could describe monitoring procedures. One couple described the AS monitoring 
experienced over almost two years as, “active monitoring and watching” (65NT) and 
“watch and wait” (61PNT). Other terms used for AS included “watch and see,” and, 
commonly, “watchful waiting”. Two partners did not realise that the men had been on 
AS. One said it was a “bit of time to think” (65PMT).  
 
Decision-making: difficulties, assistance, and rationales  
 
Men’s treatment decisions were informed by perspectives from medical staff, friends, 
colleagues, partners, and/or available information, and affected by their emotional 
reactions, cancer related memories, and lifestyle factors. Conflicting information 
related to treatment indicators could challenge. One man reported his urologist said: 
“You would be an ideal candidate (for AS)”, …yet the brochures worried 
me a bit because they seemed to say that, for relatively young men my age, 
it was not all that recommended …. Surgeons that I sort of know, and 
family, friends … stared at me in disbelief and said, “What is this AS thing? 
… take it out as soon as possible!” … then I shopped around … I felt happy 
and reassured when someone told me what I wanted to hear … “You don’t 
need to have the operation.” (50AS) 
 Eight men sought second opinions following immediate RP recommendations. 
One stated, “He (urologist) said, ‘Well you should have your prostate out. When do 
you want to do it?’ … he’s trying to push me into sort of making a decision there and 
then” (69MT). 
 Fifteen men said they made the treatment decision (Figure 1) and two partners 
perceived they shared it. Partners supported men’s final decisions. Most couples 
discussed the LPC, except one couple in a new relationship, and a partner who did not 
feel “acknowledged” when not invited to the treatment decision-making consultation 
(50PAS).  
 A man chose and two partners supported the choice of RP on diagnosis to 
eradicate the cancer because of the man’s youth, expected increased longevity, and/or 
distressing memories of cancer-related deaths. The man asserted, “Take it away, cut it 
out, get rid of it. … if you’re riddled with cancer and die a slow painful death it’s just 
not worth it” (69DT), and a partner said, “It didn’t make sense to us that we would go 
down that (AS) path ... his age, his state of mind, … he’s got a young family, … 
we’ve still got a lot of things to do” (43PDT). This group believed that avoiding 
cancer progression outweighed concerns about radical treatment side-effects.  
 
Men and partners both experience and often cope with AS  
 
Partners’ shared experience of AS and its advantages  
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Men’s and partners were usually comfortable with AS. Advantages included: time to 
accept diagnosis; avoidance or delay of sexual, incontinence, or infertility radical 
treatment side effects; increased awareness and control of men’s health; and hope for 
improved health. By using “we”, seven partners also depicted themselves on AS. One 
said, “My partner does have a cancer and we both have to live with that” (62PAS). 
When asked about AS advantages another responded, “We can delay surgery and 
delay the potential outcomes” (57PAS). Men sometimes used “we” as a colloquialism 
or to signify doctor-patient relationship, e.g., “we had the finger routine” (58MT) to 
denote digital rectal examination. 
 
Pre-existing strengths, informal supports, and maintaining “normal” life assist 
coping with AS  
 
Men and partners’ strategies for coping on AS were comparable and included positive 
self-talk, living as normally as possible, distraction, thinking of PC survivors, 
rationalising that one could die of something else, hope for new PC treatments, denial 
(thinking it could disappear), educating others about PC, acquiring information, 
continuing a healthy lifestyle, seeking reassurance, and humor. One man said, “I talk a 
lot with the blokes, having a beer and yap about it” (62AS). Partners also perceived 
that they helped men through practical tasks, attending medical appointments, 
reassurance, and/or hiding concern.  
 Men usually felt that partners, family, and friends supported AS once the 
decision was made, and that partners could help them to remember monitoring 
appointments. Further, a man without a partner also found his daughter supportive.  
 
Cancer monitoring and confidence in health professionals assist coping with AS  
 
Men were also supported by trusted healthcare professionals and having a treatment 
plan in place if needed. Monitoring results sent to men or their general practitioner 
could reassure. Occasionally men and partners found psychological counselling 
supportive. Helpful health professionals gave men enough time, quality information, 
clear answers, and were contactable and reputable. One man was “very comfortable” 
with his urologist adding, “I’d googled him. … endless qualifications, he travels 
overseas to conferences” (64AS).  
 
AS stressors are endured or inform radical treatment decision  
 
AS stressors encompass illness uncertainty, monitoring stressors, and inconsistent 
information  
 
Some men were saddened, grumpy, or anxiously feared disease progression while on 
AS. One said that many people say, 
“PSA is useless … biopsies are just not good for you.” ... Why would one 
test come back and give me a very high Gleason count and then the next 
biopsy actually says there’s nothing there? ... I’ve asked these questions but 
nobody seems to answer them. They … say, “No, no, you are fine.” … I 
keep saying to my wife, “Should I go and get another opinion … the best of 
three? (53AS)  
Another man also disliked “not doing anything” about his cancer (60AS). “Jumping” 
PSA levels or memories of inconsistent treatment recommendations on diagnosis 
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were also stressful. One man “summed” up AS as “death, dying”, and awoke “some 
mornings … really depressed” (58MT). Although initially thinking that AS was 
advantageous, another man now considered AS an “irrelevant” period of “head in the 
sand” which avoided “the inevitable” and prevented potentially less invasive 
treatment earlier (68MT). A partner also “worried” that AS was “the wrong choice 
(because) ... tests are unreliable” (42PAS). 
 Biopsy effects or waiting for results could distress men and partners. A partner 
found one of her husband’s biopsy, “so distressing … bleeding, … vomiting.’… 
Terrible” (61MT). Following one man’s multiple hospital visits for biopsy related 
infection, another partner considered it time to get “the prostate removed” (57PAS). 
Partners also sometimes worried about disease spread and the inconvenient, costly, 
time consuming, or PC threat reminder of AS monitoring. Although many thought 
that formal support would help, two partners believed this available support should 
focus on the diagnosed men. One partner also stated that family and friends without 
experience of PC “don’t probably quite understand” (57PAS). 
 Men were sometimes annoyed by their forgotten or unanswered medical 
questions (e.g., prognostic) in medical consultations, platitudes, or conflicting 
information (e.g., inconsistent interpretations about PSA levels). One man also felt 
uncomfortable asking what he considered to be “stupid questions” while on AS (e.g., 
why “I can’t pee”; 76MT). Need for clarifying information was regularly evident: One 
man questioned whether biopsies encouraged cancer growth. Another queried how 
one urologist could say, “You’ve still got cancer,” whereas another says, “You don’t 
have a problem …. The most difficult thing (he added) was getting reliable and 
personally relevant information” (60AS). Some felt that scant information received 
from doctors was due to the men’s medical background or geographical location 
(country rather than city). Occasional doctors were also perceived as fiscally focussed, 
too garrulous, or too brief.  
 
Ceasing AS is informed by personal and medical factors 
 
While most men on AS sought, or would seek, radical medical treatment when 
medically indicated, only one man considered seeking treatment if anxiety about 
illness progression further increased. Another man had RP when not medically 
indicated after almost two years on AS because of concern about cancer progression, 
and the painful biopsies prevented long-term travel plans. Partners supported men’s 
decisions.  
  
Conclusions 
 
This study highlights that many men and partners were upset by multiple 
contradictions about treatment efficacy encountered following LPC diagnosis, 
including medical opinions, advice from family and friends, and information in 
brochures and internet sites. Decisional distress experienced by men, who chose 
between AS, RP, EBRT, and RT, was comparable with decisional distress in men 
only choosing between RP, EBRT, and RT options [23], i.e., the additional AS option 
did not make treatment decision-making less stressful. Furthermore, men in this study 
regularly sought second opinions after RP was initially recommended, apparently 
aware that decision-making was not urgent. This contrasts with reports that men 
avoided second opinions to avert treatment delay when only offered radical treatment 
options [18]. 
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 The findings support previously reported AS advantages [6, 20], indications 
that men often cope4 with AS [7, 21], and reveal that many partners similarly cope 
with monitoring. However, even when men and women were coping, some remained 
encumbered by memories of contradictory LPC treatment opinions, unanswered 
questions about prognosis and symptoms, and distressing biopsy side effects. Some 
also perceived AS as, “not doing anything,” as found elsewhere [6, 22].  
 The findings reinforce that distress in men and partners following diagnosis 
[18] is compounded by bewilderment experienced during treatment decision-making. 
Men’s and partners’ confusion is understandable given contrasting expert views on 
LPC management encountered in medical consultations and gathered information. 
This reflects international, inconsistent criteria for AS eligibility [31] and expert 
dissension on clinical implications of findings from ongoing trials comparing 
observation and radical treatment [32]. Men’s and partners’ confusion intensified 
when information was old and family and friends doubted the unfamiliar AS concept. 
Even participants who had been managed with AS regularly asked the research 
interviewer to explain AS. Men’s use of multiple terms to depict AS mirrored 
international inconsistencies in descriptors for AS [8, 22] and, possibly, their doctors’ 
inaccurate terminology. Research participants’ knowledge of AS varies [20, 22] with 
this research supporting Davison and colleagues’ finding that men are often 
unfamiliar with AS even when undergoing this treatment [22]. 
To support well-being and decision-making in men diagnosed with LPC 
improved community and medical education about AS is needed, alongside consistent 
and up-to-date information on treatment options, associated prognoses, and side-
effects. When combined with values-clarification exercises, this information could 
possibly assist men’s capacity for decision-making based on personal needs and may 
reduce pressure from misinformed family and friends. As found elsewhere, occasional 
partners were distressed by men’s AS decisions and monitoring [24]. Hence, partners 
would also likely benefit from enhanced recognition within LPC information sources, 
treatment support, medical consultations, and decision aids emerging in this field [33, 
34]. Preparatory information on handling surveillance biopsy reactions is also needed, 
and ongoing support may be necessary for the significant minority of men who find 
AS difficult. This includes doctors’ abilities to elicit and address their important 
questions.  
Interestingly, men usually spoke about deciding between AS or RP, rather than 
all radical treatment options, possibly because urologists’ options reflected their 
specialty [35]. It is also possible that men rapidly differentiate and consolidate options 
to manage decisions, as espoused by decision-making theory [34, 36]. The findings 
also indicate that some men defer treatment decisions to their doctors [16, 22]. 
Although doctors should offer men unbiased opportunities for shared decision-making 
[37], which may include partners, men’s self-determined choice to not make health 
care decisions [38] should also be respected. 
 
Limitations and Further Recommendations 
The findings reflect English speaking volunteers, and the low response rate may have 
been due to some invitees not understanding “active surveillance” in participant 
invitations and consent forms. A selection bias of people with negative experiences of 
LPC decision-making and AS may have been present. The study also only recruited 
one man and two partners of men who immediately elected radical treatment. An 
                                                          
4 i.e., had or intended to continue AS until radical treatment was/is medically warranted. 
10 
                                                                                                                   What is this active surveillance thing? 
 
 
 
additional six men in this category were invited but did not respond. Possibly those 
unable to live with LPC do not want related emotions elicited in research. Further 
recruitment in this cohort may have revealed more varied treatment-decision 
reactions. Given difficulties in recruitment, sampling was arguably more convenience 
despite purposive intent. 
 A treatment decision aid for men with LPC, which emphasizes that AS is 
another treatment option and acknowledges partners/support people, is being 
developed for examination using a randomized controlled trial design. Integration of 
stories from other men and partners with LPC experiences would likely enhance 
information resources as study participants regularly desired hearing others’ reactions 
to LPC (Table 2). Development of internationally agreed LPC related descriptors and 
anticipated treatment biomarkers [39] would also reduce distress related to 
contradictory information. Future research comparing distress in subgroups involved 
with AS could elucidate those needing targeted support, e.g., men/partners, 
partnered/single men, and men with good/poor AS knowledge [20]. 
  
 In this new era which recognises the pivotal role of partners in personal health 
care planning, it is essential that discussions of treatment options and decisions are 
tailored to patient preferences for information and decision-making involvement, and 
include consideration of their values, life context, and desire for family/friend 
involvement [40]. Providing treatment information materials is also recommended 
[40]. There are no internationally accepted standards for treating and monitoring LPC. 
This study and other reports indicated that doctors offer conflicting opinions [32] and 
use inconsistent language [22] in information and materials given to patients. While 
this may not distress men who defer treatment choice to doctors, actively involved 
decision makers are gathering contradictory information from different sources. 
Consequent distress, palpable in these findings, needs to be addressed through 
offering medical explanations for inconsistent information widely available, and up-
to-date information and decision aids relevant to the personalized needs of men, 
partners, and others who support them. 
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Table 1. Participants’ demographic characteristics 
                         Men                     Partners 
           (n= 21)           (n = 141) 
____________________________________________________________________ 
Age (years)   
≤50  
51-60  
61-70  
71+  
Origin 
1 
6 
11 
3 
4 
2 
7 
1 
Australia 15 8 
Other2 6 6 
Educational Background 
Post high school qualifications 
Completed high school 
Had not completed high school 
Mean Partnership Length 
 
 
16 
3 
2 
28 years 
(range 3-50) 
 
10 
0 
4 
22 years  
(range 0-50) 
Treatment Decisions   
Still on AS 
RP after >/= 3 months on AS 
EBRT after >/= 3 months on AS 
BT after >/= 3 months on AS 
RP immediately after diagnosis 
Reasons for Ceasing AS Treatment 
Medically indicated 
Non-medically indicated 
11 
7 
1 
1 
1 
 
8 
1 
 
 
 
 
 
   
______________________________________________________________________________________________________ 
1 One male partner 
2 Men were born in England (3), Scotland, Holland, and Ethiopia. Partners were born 
in England (2), China (2), Scotland, and Indonesia.  
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Table 2. Men and Partner LPC Healthcare Recommendations1 
LPC treatment decision-making  
• Men and partner LPC stories 
• Quality, clear, consistent,  information  
Assisting AS 
• Advice on managing medical appointments (especially biopsies) 
General  
• Talking to another with similar experience 
• Formal one-to-one psychological supports 
• Access to healthcare professionals 
• Support groups  
1Made by some respondents: some may not consider the interventions are needed 
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Figure 1. Reported treatment decision pathways by men (patients) at time of 
interviews 
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